GLP-1 drugs cut heart failure events by 60% in obese HFpEF but do not reduce mortality in meta-analysis | Research

The takeaway

Meta-analysis of 3 RCTs (1,876 obese HFpEF patients) shows GLP-1 drugs significantly reduced heart failure events by 60% (RR 0.40, p=0.003), improved quality of life (+7.2 KCCQ points), and reduced weight (-9.8 kg), but did not reduce mortality.

60% fewer HF events
GLP-1 drugs dramatically reduced heart failure events (RR 0.40) in obese HFpEF but did not reduce cardiovascular or all-cause mortality in this meta-analysis

What the researchers found

HF events: RR 0.40 (p=0.003). CV mortality: RR 0.79 (NS). All-cause mortality: RR 0.98 (NS). KCCQ-CSS: +7.23 points. Weight: -9.76 kg. 6MWD: +16.54 m. GI AE discontinuation: RR 4.01. SAEs: RR 0.66 (NS). 3 RCTs, 1,876 patients.

Why it matters

This precisely quantifies the HFpEF benefit: dramatic HF event reduction and quality improvement, but no mortality benefit yet. This defines realistic expectations for GLP-1 drugs in HFpEF.

How the study worked

Systematic review and meta-analysis. Embase, PubMed, Cochrane. 3 RCTs. Random-effects model. 1,876 patients with obesity + HFpEF. Mean follow-up 69.3 weeks.

What this study cannot tell us

Only 3 RCTs available. ~70-week follow-up may be too short for mortality. GI discontinuation (RR 4.01) may limit real-world adoption. Different GLP-1 drugs pooled.

How to read the evidence

Meta-analysis of 3 RCTs. High-quality evidence for HF events and symptom outcomes. Underpowered for mortality.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs are clearly symptomatic and event-reducing in obese HFpEF but not life-saving based on current data. Longer trials or larger populations may eventually show mortality benefit.

Questions still open

Will longer-term trials show mortality benefit?
Can GI side effect management improve persistence and outcomes?
Is the 60% HF event reduction sustained beyond 70 weeks?

Common questions

Do GLP-1 drugs save lives in heart failure?

Not yet proven. This meta-analysis shows GLP-1 drugs dramatically reduce heart failure hospitalizations (by 60%) and improve symptoms, exercise capacity, and quality of life in obese HFpEF patients. However, they did not reduce death from cardiovascular causes or any cause in the current data.

Are the benefits worth the side effects?

For most patients, likely yes. The 60% reduction in heart failure events and significant quality of life improvement are meaningful. However, GI side effects caused 4x more drug discontinuation than placebo. Careful dose titration and side effect management are essential to maintain patients on therapy long enough to see benefits.

Read the original research

Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.

Diabetes, obesity & metabolism, 27(12), 7030-7039

View on PubMed ↗Publisher’s paper ↗

Citation

Talavera, Armando; Teixeira, Larissa; Klein, Benjamin; Lopes, Rodolfo A; Urina-Jassir, Daniela; Navalha, Denilsa D P; Bettinotti, Branco G M; Fernandez, Nicole; Urina-Triana, Miguel; Welty, Francine K; Mihos, Christos G; Elajami, Tarec K. (2025). Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.. Diabetes, obesity & metabolism, 27(12), 7030-7039. https://doi.org/10.1111/dom.70102